Ticagrelor is Preferred Over Clopidogrel in ACS Patients Undergoing PCI
In patients with acute coronary syndrome undergoing percutaneous coronary intervention, ticagrelor or prasugrel should be used in preference to clopidogrel 1, 2. This is the most current and definitive guideline recommendation from the 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines.
Recommended Dosing Regimens
Ticagrelor (Preferred)
- Loading dose: 180 mg orally
- Maintenance: 90 mg twice daily
- Onset of action: Within 30 minutes 3
Clopidogrel (Alternative)
- Loading dose: 300 mg orally for ACS 4
- Maintenance: 75 mg once daily
- Onset of action: 2 hours (delayed compared to ticagrelor) 3
- Note: Without loading dose, antiplatelet effect is delayed by several days 4
Clinical Reasoning for Ticagrelor Preference
The superiority of ticagrelor is based on landmark evidence showing:
- 16% reduction in major adverse cardiovascular events (9.8% vs 11.7%, P<0.001) 5
- Mortality benefit: 4.5% vs 5.9% with clopidogrel (P<0.001) 5
- Reduced myocardial infarction: 5.8% vs 6.9% (P=0.005) 5
- More rapid and predictable platelet inhibition compared to clopidogrel 3
When to Use Clopidogrel Instead
Clopidogrel remains appropriate in specific clinical scenarios:
High Bleeding Risk Patients
- Age ≥75 years
- Body weight <60 kg
- History of prior bleeding
- Patients requiring oral anticoagulation (clopidogrel is preferred in triple therapy) 2
Genetic Considerations
Critical caveat: Clopidogrel is a prodrug requiring CYP2C19 metabolism 4. Patients who are CYP2C19 poor metabolizers (homozygous for loss-of-function alleles) have significantly reduced antiplatelet effect. Consider genetic testing and use ticagrelor or prasugrel in identified poor metabolizers 4.
Drug Interactions
Avoid clopidogrel with:
- Omeprazole or esomeprazole (significantly reduce clopidogrel's antiplatelet activity) 4
- Use alternative proton pump inhibitors if needed for GI protection
Duration of Dual Antiplatelet Therapy
Standard duration: 12 months of DAPT (aspirin + P2Y12 inhibitor) for patients not at high bleeding risk 1, 2
Bleeding Risk Modification Strategies
For patients who tolerate initial DAPT with ticagrelor:
- Transition to ticagrelor monotherapy ≥1 month after PCI (discontinue aspirin) 2
- This strategy reduces bleeding while maintaining efficacy 6
For patients requiring long-term anticoagulation:
- Discontinue aspirin 1-4 weeks after PCI
- Continue P2Y12 inhibitor (preferably clopidogrel in this setting) 2
Contraindications
Absolute Contraindications (Both Agents)
- Active pathological bleeding (peptic ulcer, intracranial hemorrhage) 4
- Hypersensitivity/anaphylaxis to the drug 4
Relative Contraindications
Prasugrel-specific (not ticagrelor):
- History of stroke or TIA (increased cerebrovascular event risk: 6.5% vs 1.2%, P=0.002) 3
- Age >75 years
- Weight <60 kg
Bleeding Risk Trade-offs
Ticagrelor increases non-procedure-related bleeding (4.5% vs 3.8% with clopidogrel, P=0.03) 5, including:
- Higher rate of minor bleeding (45.5% vs 26.2% in-hospital) 7
- More fatal intracranial bleeding but fewer fatal bleedings of other types 5
- No difference in overall major bleeding rates 5
Recent evidence in anticoagulated patients shows ticagrelor increases bleeding risk (4.9% vs 3.7%, aHR 1.53) without MACE benefit 8, supporting clopidogrel preference in this population.
Common Pitfalls to Avoid
- Do not use clopidogrel without loading dose in ACS - this delays antiplatelet effect by several days 4
- Do not combine clopidogrel with omeprazole/esomeprazole - use alternative PPIs 4
- Do not stop P2Y12 inhibitors abruptly - increases cardiovascular event risk; restart as soon as possible if temporarily discontinued 4
- Do not forget to consider CYP2C19 testing in patients on clopidogrel with recurrent events 4
- Ticagrelor causes dyspnea in a significant proportion of patients - this is a known side effect but not dangerous 9
Upstream vs. Periprocedural Timing
For non-STEMI patients with invasive strategy planned >24 hours: